Evidence map›Paper›PMID 37017868›Full record

ArticlePharmacological reports : PR2023

Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study.

Małgorzata Siewierska, Mateusz Gajda, Aleksandra Opalska, Michał Brudło, Paweł Krzyściak, Barbara Gryglewska, Anna Różańska, Jadwiga Wójkowska-Mach

Abstract read
In one paragraph

Article in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Małgorzata SiewierskaDepartment of Ophthalmology, St. Rose Hospital, Kraków, Poland.
Mateusz GajdaDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Aleksandra OpalskaDirectorate-General for Health and Food Safety, European Commission, Brussels, Belgium.
Michał BrudłoDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Paweł KrzyściakDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Barbara GryglewskaDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland.
Anna RóżańskaDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.
Jadwiga Wójkowska-MachDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland. jadwiga.wojkowska-mach@uj.edu.pl.ORCID http://orcid.org/0000-0003-0756-1639

Funding

Narodowe Centrum Badań i Rozwoju SZPITALE-JEDNOIMIENNE/18/2020
6 · The paper itself

Abstract

backgroundCOVID-19 has been challenging for the entire healthcare system, due to the lack of sufficient treatment protocols, especially during initial phases and as regards antibiotic use. The aim of this study was to identify the trends of antimicrobial consumption in one of the largest tertiary hospitals in Poland during COVID-19.

methodsThis is a retrospective study conducted at the University Hospital in Krakow, Poland, between Feb/Mar 2020 and Feb 2021. It included 250 patients. All included patients were hospitalized due to COVID-19 with confirmed SARS-CoV-2 infection without bacterial co-infections during the first phase of COVID-19 in Europe and following 3-month intervals: five equal groups of patients in each. COVID severity and antibiotic consumption were assessed according to WHO recommendations.

resultsIn total 178 (71.2%) patients received antibiotics with a incidence rate of laboratory-confirmed healthcare-associated infection (LC-HAI) was 20%. The severity of COVID-19 was mild in 40.8%, moderate in 36.8%, and severe in 22.4% cases. The ABX administration was significantly higher for intensive care unit (ICU) patients (97.7% vs. 65.7%). Length of hospital stay was extended for patients with ABX (22.3 vs. 14.4 days). In total, 3 946.87 DDDs of ABXs were used, including 1512.63 DDDs in ICU, accounting for 780.94 and 2522.73 per 1000 hospital days, respectively. The median values of antibiotic DDD were greater among patients with severe COVID-19 than others (20.92). Patients admitted at the beginning of the pandemic (Feb/Mar, May 2020) had significantly greater values of median DDDs, respectively, 25.3 and 16.0 compared to those admitted in later (Aug, Nov 2020; Feb 2021), respectively, 11.0, 11.0 and 11.2, but the proportion of patients receiving ABX therapy was lower in Feb/Mar and May 2020 (62.0 and 48.0%), whereas the highest during the late period of the pandemic, i.e., in Aug, Nov. 2020 and Feb. 2021 (78% and both 84.0%).

conclusionsData suggest great misuse of antibiotics without relevant data about HAIs. Almost all ICU patients received some antibiotics, which was correlated with prolonged hospitalization.

Indexed as

COVID-19Anti-Bacterial AgentsHospitalsHumansInterrupted Time Series AnalysisPandemicsPolandRetrospective StudiesSARS-CoV-2Anti-Bacterial AgentsAntibioticsConsumptionCOVID-19Healthcare-associated infectionSARS-CoV-2

Identifiers

PMID37017868
PMCPMC10073786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.